PreAsthmaControl (PAC)

AstraZeneca logo

AstraZeneca

Status and phase

Completed
Phase 4

Conditions

Asthma

Treatments

Drug: Pulmicort (budesonide) pMDI

Study type

Interventional

Funder types

Industry

Identifiers

NCT00234390
SD-004-0299

Details and patient eligibility

About

The purpose of this study is to investigate the ability of budesonide, given during episodes of troublesome lung symptoms to reduce further symptoms in infants and young children at risk of developing asthma

Sex

All

Ages

Under 6 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Children of asthmatic mothers form the COPSAC birth cohort study

Exclusion criteria

  • Children born more than 4 weeks preterm
  • children with other systemic illness that atopy/allergy
  • Children requiring mechanical ventilation at any time since birth.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems